SCS adds to iPS portfolio
Wednesday, 08 October, 2008
Stem Cell Sciences [ASX: STC] has licensed technology developed at Cambridge University used to reprogram adult cells into stem cells.
The agreement relates specifically to patents for technology used to generate induced pluripotent stem (iPS) cells from mammalian cells.
The technology was developed by Professor Austin Smith. Smith, director of the Wellcome Trust Centre for Stem Cell Research.
Smith also serves as chairman of SCS's Scientific Advisory Board.
TGA approves first treatment for geographic atrophy
Australia has become the first country outside of the United States to approve the use of the...
Damaged RNA, not DNA, revealed as main cause of acute sunburn
Sunburn has traditionally been attributed to UV-induced DNA damage, but it turns out that this is...
Multi-ethnic studies identify new genes for depression
Two international studies have revealed hundreds of previously unknown genetic links to...
